143805-55-4

Basic information

• Product Name: Boronic acid, [4-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]phenyl]-
• CAS NO: 143805-55-4
• Molecular Formula: C18H22BNO3
• Molecular Weight: 311.189
• Mol File: 143805-55-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Boronic acid, [4-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Boronic acid, [4-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]phenyl]-(143805-55-4)
• EPA Substance Registry System: Boronic acid, [4-[[(2-ethyl-5,6,7,8-tetrahydro-4-quinolinyl)oxy]methyl]phenyl]-(143805-55-4)

Safety Data

• Hazardous Substances Data: 143805-55-4(Hazardous Substances Data)

Upstream product

• 68162-47-0 4-bromomethylphenylboronic acid 
• 138642-39-4 2-ethyl-5,6,7,8-tetrahydro-4(1H)-quinolone 

Downstream Products

• 143805-77-0 4-[(2'-cyanobiphenyl-4-yl)methoxy]-2-ethyl-5,6,7,8-tetrahydroquinoline 

Relevant articles and documents

Chemical process for making angiotesin II antagonist compounds

The invention provides a novel chemical process for the manufacture of quinoline, pyridine and imidazole derivatives of the formula IV wherein Q, Y 1 and Y 2 have the various meanings defined herein, and their non-toxic salts, which are angiotensin II inhibitors. The process involves the removal of an electron-deficient phenyl group or a pyridyl or pyrimidyl group from a compound of the formula VI as defined herein.

Angiotensin II antagonizers which are condensed pyridine derivatives

The invention concerns pharmaceutically useful novel compounds of the formula I, in which R1, R2, R3, R4, R5, R6, R7, X and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.